Brief: CNS Pharmaceuticals Engages Berry Consultants To Advise Phase 2 Trial Design
30/06/2020 13:12
June 30 (Reuters) - CNS Pharmaceuticals Inc CNSP.O :
* CNS PHARMACEUTICALS ENGAGES BERRY CONSULTANTS TO ADVISE
PHASE 2
TRIAL DESIGN
Source text for Eikon: ID:nPnbm280Za
Further company coverage: CNSP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CNS Pharmaceuticals
See all newsCNS Pharmaceuticals Q2 net loss widens, cash rises after financing
CNS Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
Brief: Cns Pharmaceuticals Appoints Rami Levin As CEO Effective Jan 1, 2026